Riaz Atif, Alam Abtahiabdullah, Saleem Nida
Nishtar Medical University and Hospital, Multan, Pakistan.
Pak J Pharm Sci. 2023 Jan;36(1):67-70.
For prevention against SARS-CoV-2, various vaccines have been approved globally including Pfizer, Sinopharam, Moderna, Johnson & Johnson etc which have proved quite effective. To evaluate the immunization and safety of Sinopharm vaccine in cancer patients. A prospective study was conducted in the Oncology Department of Nishtar Medical Hospital, Multan from March 2021- September 2021. A total of 150 cancer patients undergoing treatment were included in the study. All the patients were administered 0.5 ml Sinopharm vaccine with 28 day difference between the two doses. A two-month follow-up was done to test the immunization using ELISA kits. Among all the patients, 16 patients (10.7%) had a history of COVID-19 before the administration of the vaccine. At the time of vaccination, 23.3% of patients were seropositive. After the vaccination, 130 patients (86.7%) developed immunity against the infection. 30.6% of participants developed a fever and 20.9% had fatigue. Other side effects were also observed including pain, redness, swelling, itching, chills, anorexia, nausea, vomiting, myalgia and diarrhea. Sinopharm vaccine is effective and safe for patients with malignancies especially in patients receiving radiaton therapy but still recommended for older patients and patients receiving chemotherapy.
为预防新型冠状病毒肺炎（SARS-CoV-2），全球已批准了多种疫苗，包括辉瑞、国药、莫德纳、强生等，这些疫苗已被证明相当有效。为评估国药疫苗在癌症患者中的免疫效果和安全性，2021年3月至2021年9月在木尔坦尼什塔尔医学院附属医院肿瘤科进行了一项前瞻性研究。共有150名正在接受治疗的癌症患者纳入该研究。所有患者均接种0.5毫升国药疫苗，两剂之间间隔28天。采用酶联免疫吸附测定（ELISA）试剂盒进行为期两个月的随访以检测免疫情况。在所有患者中，16名患者（10.7%）在接种疫苗前有新型冠状病毒肺炎病史。接种疫苗时，23.3%的患者血清呈阳性。接种疫苗后，130名患者（86.7%）产生了针对该感染的免疫力。30.6%的参与者出现发热，20.9%的参与者感到疲劳。还观察到其他副作用，包括疼痛、发红、肿胀、瘙痒、寒战、食欲不振、恶心、呕吐、肌痛和腹泻。国药疫苗对恶性肿瘤患者有效且安全，尤其是对接受放射治疗的患者，但仍建议老年患者和接受化疗的患者接种。
